Trials / Withdrawn
WithdrawnNCT04364217
Pain and Itch Reduction in Burn Scars Treated With Fractional CO2 Laser
Evaluating the Mechanism of Pain and Itch Reduction in Burn Scars Following Fractional Ablative CO2 Laser Treatment
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Hypertrophic Burn Scars (HTBS) are often treated with Fractional CO2 laser therapy to improve cosmetic appearance. It has been noted that this leads to a reduction in the pain and itch associated with this type of scars. While this phenomenon is commonly described in the literature, the mechanism of pain and itch reduction in unclear. The investigators aim to better understand this process by histological evaluation of HTBS at different stages of laser treatment.
Detailed description
During our study, patients with painful and/or itchy burn scars will undergo standard treatment with fractional CO2 laser. In addition to the standard of care treatment, participants will undergo skin biopsies and be asked to complete Patient Reported Outcome Measure questionnaires related to their HTBS. Burn scars will also undergo standard and 3 dimensional photography at the different stages of treatment. Biopsy samples will undergo various staining techniques to establish the changes in tissue that occur with the laser treatment. This information will also be correlated with the symptomatic changes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Luminis ultrapulse fractional ablative carbon dioxide laser | This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep. |
Timeline
- Start date
- 2020-06-25
- Primary completion
- 2025-03-01
- Completion
- 2025-07-01
- First posted
- 2020-04-28
- Last updated
- 2025-12-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04364217. Inclusion in this directory is not an endorsement.